SELP and COVID-19: Due to the increased risk of morbid sequelae in COVID-19 patients, more large-scale prospective trials to examine the usefulness of P-selectin as a platelet and endothelial activation marker, to stratify risk, and for unfavorable prognostic outcomes are urgently needed.